Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q6PCB5
UPID:
RSBNL_HUMAN
Alternative names:
Round spermatid basic protein 1-like protein
Alternative UPACC:
Q6PCB5; C9K0P1; Q6ZS58; Q6ZVI9; Q86X48
Background:
Lysine-specific demethylase RSBN1L, also known as Round spermatid basic protein 1-like protein, plays a crucial role in epigenetic regulation by specifically demethylating methylated lysine residues of proteins. This process is vital for the modulation of gene expression, impacting cellular differentiation, and development.
Therapeutic significance:
Understanding the role of Lysine-specific demethylase RSBN1L could open doors to potential therapeutic strategies. Its unique function in the regulation of gene expression through demethylation makes it a promising target for drug discovery, aiming to correct epigenetic malfunctions associated with various diseases.